MCRB · Seres Therapeutics Inc
United States · RS rating 4 · As of 2026-11-03
| Price | 1.96 USD |
|---|---|
| 1-day change | +7.1% |
| RS rating (overall / 1M / 3M / 12M) | 4 / 11 / 6 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 5 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +122.6% |
| Sales growth Q/Q | -54.6% |
| Distance from 52-week high | +93.2% |
| Market cap (USD) | $77.6M |